Optimizing Adjuvant Treatment Recommendations for Older Women with Biologically Favorable Breast Cancer: Short-Course...

Area of Science:

• Oncology
• Radiation Oncology
• Endocrine Therapy

Background:

• Adjuvant endocrine therapy is standard for hormone-sensitive early-stage breast cancer post-breast-conserving surgery.
• Endocrine therapy toxicities are significant, especially in elderly patients with comorbidities, leading to poor adherence.
• Radiotherapy monotherapy is an alternative for select patients, but endocrine therapy omission in this context is less studied.

Purpose of the Study:

• To review existing data on omitting endocrine therapy in patients receiving adjuvant radiation for early-stage breast cancer.
• To evaluate the efficacy and safety of radiation monotherapy without endocrine therapy.
• To highlight the need for prospective randomized trials investigating endocrine therapy omission.

Main Methods:

• Review of available randomized and non-randomized outcome data.
• Analysis of local control and survival rates in patients treated with radiation monotherapy.
• Focus on select patient populations, including older women and those with comorbidities.

Main Results:

• Available data suggest that omitting endocrine therapy in conjunction with radiation monotherapy may achieve comparable local control and survival for select patients.
• Evidence for endocrine therapy omission alongside radiation is less robust than for radiotherapy omission alongside endocrine therapy.
• Further research is needed to confirm these findings and establish optimal patient selection criteria.

Conclusions:

• Omission of adjuvant endocrine therapy in favor of radiation monotherapy is a viable option for select early-stage breast cancer patients.
• Careful patient selection is crucial when considering endocrine therapy omission.
• Prospective randomized trials are essential to definitively establish the role and safety of endocrine therapy omission in this setting.